Results 81 to 90 of about 20,563 (225)

Coexistência de infeções oportunistas pulmonares num doente com infeção por vírus da imunodeficiência humana e uma forma persistente de pneumonia por Pneumocystis jirovecii: caso clínico

Revista Portuguesa de Pneumologia, 2013
Resumo: Como é sabido, nos doentes com infeção por vírus da imunodeficiência humana (VIH) existe um alto risco de ocorrência de infeções oportunistas (IO), tais como as infeções por Pneumocystis jirovecii, um agente patogénico com distribuição mundial ...
D. Ponces Bento, F. Esteves, O. Matos, A.C. Miranda, F. Ventura, C. Araújo, K. Mansinho   +6 more
doaj   +1 more source

Humans Are Selectively Exposed to Pneumocystis jirovecii

mBio, 2020
Environmental exposure has a significant impact on human health. While some airborne fungi can cause life-threatening infections, the impact of environment on fungal spore dispersal and transmission is poorly understood.
Ousmane H. Cissé, Liang Ma, Chao Jiang, Michael Snyder, Joseph A. Kovacs   +4 more
doaj   +1 more source

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

Arthritis &Rheumatology, Volume 78, Issue 3, Page 509-522, March 2026.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian, Sophie Georgin‐Lavialle, Marcela A. Ferrada, Sinisa Savic, Matthew J. Koster, Olivier Kosmider, Thibault Comont, Mael Heiblig, Juan I. Arostegui, Annmarie Bosco, Rim Bourguiba, Katherine R. Calvo, Catherine Cargo, Chiara Cattaneo, François Chasset, Henrique Coelho, Corrado Campochiaro, Francesca Crisafulli, Stephanie Ducharme‐Benard, Raquel Faria, Franco Franceschini, Micol Frassi, Emma M. Groarke, Carmelo Gurnari, Yervand Hakobyan, Yvan Jamilloux, Ciprian Jurcut, Yohei Kirino, Austin Kulasekararaj, Hiroyoshi Kunimoto, Lauren M. Madigan, Heřman F. Mann, Chiara Marvisi, Marcin Milchert, Sara Morais, Katja Sockel, Francesco Muratore, Hideaki Nakajima, Mrinal M. Patnaik, Luísa Regadas, Marie Robin, Abraham Rutgers, Carlo Salvarani, Anthony M. Sammel, Joerg Seebach, Pierre Sujobert, Alessandro Tomelleri, Geoffrey Urbanski, Frédéric Vandergheynst, Romana Vieira, David S. Viswanatha, Ewa Więsik‐Szewczyk, Elisa Diral, Benjamin Terrier, Bhavisha A. Patel, Pierre Fenaux, Peter C. Grayson, David B. Beck, on behalf of the International VEXAS working group, and with endorsement of EuroBloodNet, the European Reference Network in Rare Hematological Diseases, Heřman Mann, Benjamin Terrier, François Chasset, Sophie Georgin Lavialle, Alessandro Tomelleri, Campochiaro Corrado, Carlo Salvarani, Francesca Crisafulli, Franco Franceschini, Micol Frassi, Yohei Kirino, Ewa Więsik‐Szewczyk, Marcin Milchert, Raquel Faria, Ciprian Jurcut, Joerg Seebach, Sinisa Savic, David Beck, Lauren Madigan, Matthew Koster, Patnaik Mrinal, Olivier Kosmider, Pierre Sujobert, Juan I. Arostegui, Catherine Cargo, David Viswanatha, Yervand Hagopian, Mael Heilblig, Pierre Fenaux, Thibault Comont, Bruno Alessandro, Chiara Cattaneo, Elisa Diral, Sara Morais, Austin Kulasekarara, Emma Groarke, Katherine Calvo, Patel Bhavisha, Anthony Sammel, Arsene Mekinian, Benjamin Terrier, Marie Robin, Sophie Georgin Lavialle, Katja Sockel, Yvan Jamilloux, Carmelo Gurnari, Henrique Coelho, Romana Vieira, Rim Bourguiba, Marcela Ferrada, Peter Grayson   +111 more
wiley   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, Volume 78, Issue 3, Page 566-581, March 2026.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

The Drug Safety Framework of Avacopan: A Pharmacovigilance Study

Medicine Advances, Volume 4, Issue 1, Page 77-89, March 2026.
We identified 11 previously unreported potential adverse events associated with avacopan. No high‐priority clinical events were observed; however, special attention should be paid to the potential possibility of avacopan‐induced vanishing bile duct syndrome (Logos and icons displayed in the sections “Safety Framework” and “Data Sources and ...
Tianqi Chang, Xiaohong Xin, Xian Shao, Dikang Pan, Jingyu Wang   +4 more
wiley   +1 more source

The Evolution of Pneumocystis jirovecii Pneumonia Prophylaxis for Pediatric Patients With Extracranial Solid Tumors: A Review of Historical Insights and Future Directions

Pediatric Blood &Cancer, Volume 73, Issue 3, March 2026.
ABSTRACT Pneumocystis jirovecii pneumonia (PJP) remains a modern‐day complication for pediatric patients receiving treatment for extracranial solid tumors (ST), highlighting the need for reconsideration of our current approach toward PJP prophylaxis. This critical review aims to evaluate both universal and risk‐stratified approaches to PJP prophylaxis ...
Kriti Kumar, Denise M. Connolly, Ellen Kellington, Elyse Zelunka, Karla Kerrigan, Furqan Shaikh, Paul C. Nathan, Meredith S. Irwin, Sarah Cohen‐Gogo   +8 more
wiley   +1 more source

Cohort Study to Determine the Impact of CYP3A5 Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Heart Transplant Recipients

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 3, March 2026.
ABSTRACT Background Tacrolimus is primarily metabolized by Cytochrome P450 (CYP)3A4/5. The Clinical Pharmacogenetics Implementation Consortium recommends increasing the initial dose 1.5‐ to 2‐fold in CYP3A5 expressers to enhance transplant outcomes. Our objective was to investigate the impact of CYP3A5 expresser status on tacrolimus dosing requirements
Yanting Wu, Michael T. Eadon, Laurie Schenkelberg, Roopa A. Rao, Todd C. Skaar, Emma M. Tillman, Tyler Shugg   +6 more
wiley   +1 more source

Advanced Fungal Control With Metallic Nanoparticles: A Comprehensive Review of Nanoparticle Tracking Analysis (NTA) for Particle Concentration Characterization

ChemistrySelect, Volume 11, Issue 12, 26 March 2026.
Metallic nanoparticles are emerging as potent antifungal agents, yet their efficacy is rarely quantified on a particle basis. Here, we demonstrate how nanoparticle tracking analysis (NTA), together with a newly proposed Particle Efficiency Index (PEI), can relate nanoparticle concentration to fungal inoculum load, enabling more rigorous and comparable ...
Rodrigo Ramos‐Hernández, Abraham Méndez‐Albores, Alma Vázquez‐Durán   +2 more
wiley   +1 more source

A Meta‐Analysis on the Incidence and Associated Factors of Pulmonary Fungal Infections in Lung Cancer Patients: Evidence Predominantly From Chinese Studies in the Chinese and English Literature

Thoracic Cancer, Volume 17, Issue 6, March 2026.
This study aimed to estimate the incidence and risk factors of pulmonary fungal infections in lung cancer patients through a meta‐analysis of Chinese and English studies (up to April 2025). The findings indicated that: (1) Incidence: 14.0% (95% CI, 12.54%–15.45%); (2) Major Risk Factors: (a) Demographic: Age ≥ 60 years, male, smoking history.
Liping Deng, Rong Yu, Bei Chen
wiley   +1 more source

Dihydropteroate Synthase Gene Mutations in Pneumocystis and Sulfa Resistance

Emerging Infectious Diseases, 2004
Pneumocystis pneumonia (PCP) remains a major cause of illness and death in HIV-infected persons. Sulfa drugs, trimethoprim-sulfamethoxazole (TMP-SMX) and dapsone are mainstays of PCP treatment and prophylaxis.
Laurence Huang, Kristina Crothers, Chiara Atzori, Thomas Benfield, Robert Miller, Meja Rabodonirina, Jannik Helweg-Larsen   +6 more
doaj   +1 more source